Important Securities Class Action Filed Against Capricor Therapeutics: Deadline Approaches in 2026

Capricor Therapeutics Faces Securities Class Action Amidst Legal Challenges

Capricor Therapeutics, Inc. (NASDAQ: CAPR) has recently come into the spotlight due to a securities class action being filed against it, which has raised significant concerns among its investors. The firm SueWallSt has issued a reminder to shareholders of the impending deadline for participating in this class action, scheduled for September 28, 2026.

What’s at Stake?

The crux of the class action lawsuit revolves around allegations that Capricor Therapeutics did not adhere to its predetermined blinding and protocol procedures during the Phase 3 HOPE-3 trial. This lack of compliance raises critical questions regarding the integrity of the trial, as it deviated from the approved statistical analysis plan (SAP) noted by the FDA. Potential investors are urged to consider these details when evaluating their stakes in the company.

Falling Stock Prices

On July 24, 2026, Capricor's stock price peaked at $19.70 before plummeting to $4.19 by July 27, a staggering decrease of about 78.7%. This drastic decline resulted in an aggregate corrective-disclosure loss of approximately $15.08 per share, significantly impacting investors who may not have been fully aware of the developments surrounding the trial and subsequent stock performance.

The Allegations Unfolded

The class action suit details several key failures in adherence to the trial protocol, specifically highlighting changes made to the statistical plan post-data unblinding, which allegedly modified pivotal endpoint definitions and analytical methods. These alterations not only compromise the results but may also have influenced shareholder information during the trial's progression.

The FDA noted discrepancies in the submitted analysis, labeling some findings as post-hoc and exploratory, which raises questions about the validity of the overall trial efficacy.

What Shareholders Were Not Informed

Plaintiffs allege that Capricor's public communications emphasized misleadingly positive results, such as statistically significant outcomes in the trial while glossing over the underlying issues with trial conduct. Following the release of FDA briefing documents, revealing negative assessments of the trial outcomes, Capricor's shares sharply declined.

Next Steps for Investors

Capricor investors who purchased shares between December 17, 2025, and July 26, 2026, and subsequently suffered financial losses might qualify for recovery under this class action. To secure their eligibility, these investors should promptly gather their brokerage records, including relevant purchase dates and share quantities. No immediate action is required, but investors are encouraged to reach out to legal representation for an evaluation of their case.

How to Participate

Interested shareholders can contact Joseph E. Levi, Esq. of SueWallSt, either via email or phone, to determine their eligibility and discuss further action. Questions regarding the class action, such as the role of a lead plaintiff or costs involved in participation, can also be addressed to ensure that shareholders are adequately informed.

Conclusion

The upcoming deadline on September 28, 2026, serves as a crucial date for Capricor Therapeutics investors to consider their options regarding the ongoing class action lawsuit. With the complexities of the trial and potential for significant financial ramifications, staying informed and proactive is essential for affected shareholders.

For further information or to seek legal counsel regarding this matter, investors can connect with SueWallSt and explore their rights in this unfolding legal situation.